We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan

By LabMedica International staff writers
Posted on 24 Aug 2026

Molecular profiling is central to precision oncology in lung cancer, but tissue samples can be limited and minimally invasive approaches are often preferable. More...

Liquid biopsy enables blood-based genomic analysis when tissue is scarce, reducing reliance on invasive procedures. A new collaboration will now deploy a validated next-generation sequencing assay to analyze circulating cell-free DNA and RNA in patients with lung cancer across a large Japanese research network.

Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience have announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer in Japan. As part of the collaboration, Pillar’s oncoReveal Essential+ assay has been validated at LSI Medience for screening circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) from participants in the LC-SCRUM-Asia project. Following approval of a revised project protocol, testing is expected to begin in August 2026 and include approximately 2,000 patients over two years.

The oncoReveal Essential+ assay will be used to support targeted next‑generation sequencing from blood-based specimens within a decentralized laboratory workflow. Testing will be performed by LSI Medience to support identification of genomic alterations relevant to the project’s research objectives. By combining analysis of cfDNA and cfRNA, the project is designed to enable broad screening for genomic alterations in patients with lung cancer.

LC‑SCRUM‑Asia is a large‑scale lung cancer genomic screening and clinical research network in Japan led by the National Cancer Center Hospital East. The project brings together medical institutions, diagnostic laboratories, pharmaceutical companies, and other research partners to identify genomic alterations in patients with lung cancer and facilitate the development and delivery of biomarker‑driven therapies. Through comprehensive molecular screening and collaboration across participating institutions, LC‑SCRUM‑Asia seeks to advance precision medicine and expand clinical research opportunities for patients with lung cancer.

“LC-SCRUM-Asia has established an important collaborative framework for advancing precision oncology research in lung cancer. We are pleased that oncoReveal Essential+ has been validated at LSI Medience for screening both cfDNA and cfRNA samples and look forward to supporting this large-scale project in Japan,” said Daniel Harma, Chief Commercial Officer, Pillar Biosciences.

“Rapid and reliable genomic testing is essential for identifying patients who may benefit from biomarker-driven clinical studies and emerging precision therapies. The use of oncoReveal Essential+ through LSI Medience will provide the LC-SCRUM-Asia network with a highly accurate and accessible liquid biopsy solution for analyzing cfDNA and cfRNA from patients with non-small cell lung cancer, while supporting the rapid turnaround needed for clinical research,” said Dr. Koichi Goto of LC-SCRUM-Asia.

Related Links
Pillar Biosciences
LSI Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.